Davita stock
Price history
+39.60% over the period1 year: from $115.35 (November 20, 2025) to $161.03 (November 20, 2026), +39.60%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $161.03 |
| October 30, 2026 | $187.50 |
| September 30, 2026 | $174.92 |
| August 31, 2026 | $176.01 |
| July 31, 2026 | $240.09 |
| June 30, 2026 | $222.48 |
| May 29, 2026 | $194.36 |
| April 30, 2026 | $155.14 |
| March 31, 2026 | $153.69 |
| February 27, 2026 | $156.30 |
| January 30, 2026 | $109.34 |
| December 31, 2025 | $113.61 |
| November 28, 2025 | $119.68 |
| November 20, 2025 | $115.35 |
At a glance
The company
Provides kidney dialysis services and related lab services for chronic kidney failure patients in the United States
Latest results
Quarter to September 30, 2026 · EPS $3.82 (estimate $3.55)
TickerLandia's take on Davita
- Pricier than usual relative to earnings: P/E on the latest fiscal year 16 vs a median of 14 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 12 vs 17 (−28%) in a group of 11.
- Strong point: Profitability (56/100 in its group). Weak point: Financial strength (30/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−34.93% from the 52-week high
Analysts · 8 analysts
Average target$222.29+38.04% vs. price
Buy 3 · Hold 3 · Sell 2 · Buy
TickerLandia Fingerprint: Davita
Compared with similar companies: low price and low financial strength.
Financials and price compared with 19 companies in the medical care facilities industry, worldwide. Momentum and risk compared with 888 North American stocks.
Pricelow20
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 12.2 14 Forward P/E 9.52 14 EV/EBITDA 8.67 24 Price/sales 0.71 29 Profitabilityaverage56
How much it earns on revenue and capital.
Metric Value Position in group ROA 7.6% 61 Operating margin 15.2% 50 ROE 96.8% 97 Gross margin 32.3% 45 Net margin 6.5% 29 Earnings stabilityaverage49
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.9% 39 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 58 Growthaverage48
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +5.53% 24 Revenue growth (year over year) +4.60% 29 Earnings growth (year over year) +66.70% 92 Financial strengthlow30
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 3.57 24 Current ratio 1.41 76 Debt/equitycounts in reverse: lower means more financial strength 11.9 3 Net debt/EBITDAcounts in reverse: lower means more financial strength 4.43 18 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumaverage47
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +1.61% 48 Relative strength (6 months) −12.02% 22 1-year return +39.60% 86 Distance from 200-day average −11.43% 32 Riskaverage46
How much the price swings.
Metric Value Position in group Volatility (60 days) 41.7% 63 Beta (1 year) −0.05 12 Maximum drawdown (12 months) 35.1% 63
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Davita is pricier than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Davita's P/E today is 16.4, above the median of its last 10 fiscal years (14.2; between 11.5 and 55.9 from 2016 to 2025). Davita's P/E (trailing 12 months): 12.2, −28% against the median of a group of 11 similar companies (16.9).
Compared with 11 similar companies
| Metric | Davita | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 12.2 | Low | |
| Forward P/E | 9.52 | Low | |
| Operating margin | 15.2% | Middle | |
| ROE | 96.8% | High | |
| Debt/equity | 11.9 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Davita. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$3.58B
Latest quarter · Q3 2026
Net income
$222.93M
Latest quarter · Q3 2026
Quarterly net margin
6.2%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $10.13B
- P/E
- 12.2
- EPS
- $13.21
- Volume
- 730.12K
- Daily trading
- €141.98M
- Dividend yield
- 0.00%
How Davita is changing
All resultsRevenue grew 3.4% a year on average over the last 5 years
Operating margin rose from 11.5% to 15.0%
Profits turn into cash: free cash flow equal to 180% of net income
Returns
Davita returns
$1,000 invested in Davita 5 years ago, on November 22, 2021, would be worth $1,568 today: +56.84% in total, +9.43% per year. This is the price return only: dividends are excluded.
| Period | Davita | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | −8.17% | −10.40% | $918 |
| 6 months | −18.20% | −7.03% | $818 |
| Year to date | +41.74% | +0.95% | $1,417 |
| 1 year | +39.60% | +5.68% | $1,396 |
| 3 years | +65.11% | +51.96% | $1,651 |
| 5 years | +56.84% | +47.57% | $1,568 |
| 10 years | +156.21% | +214.37% | $2,562 |
Over the last 6 months it has done better than 11% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Davita: technical analysis
Davita shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 33.2% below its all-time closing high ($240.96, July 29, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 36
- Between 30 and 70
- vs 200-session average
- −11.43%
Active signals
Death cross: the 50-session average has crossed below the 200-session average.
since November 19, 2026
Support and resistance
Price areas where Davita has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$196.36+21.94%2 touches, last on October 29, 2026
- Resistance$191.39+18.85%2 touches, last on October 20, 2026
- Resistance$171.90+6.75%4 touches, last on October 30, 2026
- Last price$161.03
- Support$156.54−2.79%5 touches, last on April 23, 2026
- Support$145.58−9.59%5 touches, last on May 5, 2026
- Support$122.44−23.97%2 touches, last on December 11, 2025
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- −0.05
- Volatility (60 sessions, annualised)
- 41.7%
- Largest fall in the last year
- −35.12%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Davita: seasonality
Average monthly price change over 31 years
Over the last 31 years, the strongest month for Davita has been November: +5.09% on average, positive in 19 years out of 31. The weakest has been August: −1.41% on average, positive in 13 years out of 31.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.27% | +1.03% | 16 of 31 |
| February | −0.78% | −0.16% | 15 of 31 |
| March | +1.96% | +0.30% | 17 of 31 |
| April | +2.55% | +0.94% | 20 of 31 |
| May | +2.68% | +2.47% | 19 of 31 |
| June | +4.85% | +2.41% | 19 of 31 |
| July | −0.51% | +0.21% | 17 of 31 |
| August | −1.41% | −1.17% | 13 of 31 |
| September | +1.64% | +1.24% | 17 of 31 |
| October | +0.40% | +0.70% | 16 of 31 |
| November | +5.09% | +1.32% | 19 of 31 |
| December | +4.05% | +2.15% | 18 of 31 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Davita and its competitors
Based in Denver, Colorado, DaVita Inc. has existed since 1994 and works in dialysis. Its core business is treating patients whose kidneys have lost their function, delivered mainly through outpatient dialysis centers in the United States, with hospital inpatient and home-based hemodialysis also offered. Alongside these treatments, the group runs clinical laboratories serving dialysis patients, provides management and administrative services to outpatient dialysis centers, and offers integrated care, disease management and physician services. It also holds a transplant software business and conducts clinical research programs.
- Headquarters
- Denver, United States
- Employees
- 78,000
- Founded
- 1994
- Chief executive
- Javier Rodriguez
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| DavitaDVA | $10.13B | 15.2% | 12.2 | −18.20% |
| Ensign GroupENSG | $10.29B | 8.8% | 26.2 | −1.09% |
| Universal Health ServicesUHS | $10.34B | 10.9% | 7.51 | +9.20% |
| Encompass HealthEHC | $13.11B | 18.4% | 21.4 | +26.10% |
| Tenet HealthcareTHC | $20.95B | 19.1% | 7.68 | +40.44% |
| HCA HealthcareHCA | $99.34B | 15.3% | 15.8 | +19.89% |
Same industry or related industries, similar size. Compare Davita with its competitors · Full profile
